KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: A study of 56 cases

British Journal of Cancer

Volumn 109, Issue 3, 2013, Pages 559-564

  Zebary, A ^a   Jangard, M ^b   Omholt, K ^a   Ragnarsson Olding, B ^a   Hansson, J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MICRODISSECTION; NOSE CAVITY; ONCOGENE; ONCOGENE KIT; ONCOGENE N RAS; PARANASAL SINUS; PRIORITY JOURNAL; SINONASAL MUCOSAL MELANOMA; TUMOR CELL;

AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; LASER CAPTURE MICRODISSECTION; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PARAFFIN EMBEDDING; PARANASAL SINUS NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; SURVIVAL RATE;

EID: 84883154633     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.373     Document Type: Article

References (32)

1. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R (2013) MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 14: 249-256.
2. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL (2008) KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 14: 6821-6828.
3. Bradley PJ (2006) Primary malignant mucosal melanoma of the head and neck. Curr Opin Otolaryngol Head Neck Surg 14: 100-104.
4. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK (2011) KIT as a therapeutic target in metastatic melanoma. JAMA 305: 2327-2334.
5. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, Group B-S (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
6. Clifton N, Harrison L, Bradley PJ, Jones NS (2011) Malignant melanoma of nasal cavity and paranasal sinuses: report of 24 patients and literature review. J Laryngol Otol 125: 479-485.
7. Cohen Y, Rosenbaum E, Begum S, Goldenberg D, Esche C, Lavie O, Sidransky D, Westra WH (2004) Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res 10: 3444-3447.
8. Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24: 4340-4346.
9. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353: 2135-2147.
10. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
11. Edlundh-Rose E, Egyházi S, Omholt K, Månsson-Brahme E, Platz A, Hansson J, Lundeberg J (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16: 471-478.
12. Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA (2011) Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 17: 229-235.
13. Handolias D, Salemi R, Murray W, Tan A, Liu W, Viros A, Dobrovic A, Kelly J, McArthur GA (2010) Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res 23: 210-215.
14. Harbo G, Grau C, Bundgaard T, Overgaard M, Elbrond O, Sogaard H, Overgaard J (1997) Cancer of the nasal cavity and paranasal sinuses. A clinico-pathological study of 277 patients. Acta Oncol 36: 45-50.
15. Hocker T, Tsao H (2007) Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 28: 578-588.
16. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339: 959-961.
17. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339: 957-959.
18. Jangard M, Hansson J, Ragnarsson-Olding B (2013) Primary sinonasal malignant melanoma: a nationwide study of the Swedish population, 1960-2000. Rhinology 51: 22-30.
19. Jethanamest D, Vila PM, Sikora AG, Morris LGT (2011) Predictors of survival in mucosal melanoma of the head and neck. Ann Surg Oncol 18: 2748-2756.
20. Jovanovic B, Kröckel D, Linden D, Nilsson B, Egyhazi S, Hansson J (2008) Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. J Invest Dermatol 128: 2696-2704.
21. Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lu A, Guo J (2011) Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 17: 1684-1691.
22. Lee JH, Choi JW, Kim YS (2011) Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 164: 776-784.
23. Liétin B, Montalban A, Louvrier C, Kemeny JL, Mom T, Gilain L (2010) Sinonasal mucosal melanomas. Eur Ann Otorhinolaryngol Head Neck Dis 127: 70-76.
24. Lund VJ, Chisholm EJ, Howard DJ, Wei WI (2012) Sinonasal malignant melanoma: an analysis of 115 cases assessing outcomes of surgery, postoperative radiotherapy and endoscopic resection. Rhinology 50: 203-210.
25. Norlander T, Frodin JE, Silfversward C, Anggard A (2003) Decreasing incidence of malignant tumors of the paranasal sinuses in Sweden. An analysis of 141 consecutive cases at Karolinska Hospital from 1960 to 1980. Ann Otol Rhinol Laryngol 112: 236-241.
26. Omholt K, Grafström E, Kanter-Lewensohn L, Hansson J, Ragnarsson-Olding BK (2011) KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res 17: 3933-3942.
27. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J (2003) NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9: 6483-6488.
28. Schoenewolf NL, Bull C, Belloni B, Holzmann D, Tonolla S, Lang R, Mihic-Probst D, Andres C, Dummer R (2012) Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. Eur J Cancer 48: 1842-1852.
29. The National Board of Health and Welfare (1960-2009) The Swedish Cancer Registry: Cancer in Sweden. National Board of Health and Welfare: Stockholm.
30. Turri-Zanoni M, Medicina D, Lombardi D, Ungari M, Balzarini P, Rossini C, Pellegrini W, Battaglia P, Capella C, Castelnuovo P, Palmedo G, Facchetti F, Kutzner H, Nicolai P, Vermi W (2012) Sinonasal mucosal melanoma: molecular profile and therapeutic implications from a series of 32 cases. Head Neck; epub ahead of print 12 July 2012; doi:10.1002/hed.23079.
31. Ward AF, Braun BS, Shannon KM (2012) Targeting oncogenic Ras signaling in hematologic malignancies. Blood 120: 3397-3406.
32. Woodman SE, Davies MA (2010) Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80: 568-574.